Erlotinib Pathway, Pharmacokinetics

Pathway network for the Erlotinib Pathway, Pharmacokinetics SuperPath

Sources:

PharmGKB

Pathways in the Erlotinib Pathway, Pharmacokinetics SuperPath

#	Name	Source	Genes
1	Erlotinib Pathway, Pharmacokinetics	PharmGKB	ABCB1 ABCG2 CYP1A1 CYP1A2 CYP3A4 CYP3A5 EGFR UGT1A1 (see all 8) (see less)
2	Gefitinib Pathway, Pharmacokinetics	PharmGKB	ABCB1 ABCC10 ABCG2 CYP1A1 CYP2D6 CYP3A4 CYP3A5 EGFR UGT1A1 UGT1A7 UGT1A9 UGT2B7 (see all 12) (see less)
3	Dasatinib Pathway, Pharmacokinetics	PharmGKB	ABCB1 ABCG2 CYP1A1 CYP1A2 CYP1B1 CYP2C9 CYP3A4 CYP3A5 FMO3 UGT1A1 UGT1A9 UGT2B15 (see all 12) (see less)

Gene overlap in member pathways for Erlotinib Pathway, Pharmacokinetics SuperPath

Ordered by rank within the SuperPath, via the multiplicity of each gene in the constituent pathways

#	Symbol	Description	Category	# Related Pathways
1	UGT1A1	UDP Glucuronosyltransferase Family 1 Member A1	Protein Coding	3
2	ABCB1	ATP Binding Cassette Subfamily B Member 1	Protein Coding	3
3	CYP1A1	Cytochrome P450 Family 1 Subfamily A Member 1	Protein Coding	3
4	CYP3A4	Cytochrome P450 Family 3 Subfamily A Member 4	Protein Coding	3
5	CYP3A5	Cytochrome P450 Family 3 Subfamily A Member 5	Protein Coding	3
6	ABCG2	ATP Binding Cassette Subfamily G Member 2 (JR Blood Group)	Protein Coding	3
7	EGFR	Epidermal Growth Factor Receptor	Protein Coding	2
8	CYP1A2	Cytochrome P450 Family 1 Subfamily A Member 2	Protein Coding	2
9	UGT1A9	UDP Glucuronosyltransferase Family 1 Member A9	Protein Coding	2
10	UGT2B7	UDP Glucuronosyltransferase Family 2 Member B7	Protein Coding	1
11	UGT1A7	UDP Glucuronosyltransferase Family 1 Member A7	Protein Coding	1
12	CYP2D6	Cytochrome P450 Family 2 Subfamily D Member 6 (Gene/Pseudogene)	Protein Coding	1
13	ABCC10	ATP Binding Cassette Subfamily C Member 10	Protein Coding	1
14	UGT2B15	UDP Glucuronosyltransferase Family 2 Member B15	Protein Coding	1
15	FMO3	Flavin Containing Dimethylaniline Monoxygenase 3	Protein Coding	1
16	CYP1B1	Cytochrome P450 Family 1 Subfamily B Member 1	Protein Coding	1
17	CYP2C9	Cytochrome P450 Family 2 Subfamily C Member 9	Protein Coding	1

Disorders associated with Erlotinib Pathway, Pharmacokinetics SuperPath

according to GeneCards Suite gene sharing

#	Disorder	Type	Genes	Score
1	Crigler-najjar syndrome, type i	Enrichment	UGT1A1, UGT1A7, UGT1A9	7.20
2	Hyperbilirubinemia, transient familial neonatal	Enrichment	UGT1A1, UGT1A7, UGT1A9	7.20
3	Bilirubin, serum level of, quantitative trait locus 1	Enrichment	UGT1A1, UGT1A7, UGT1A9	7.20
4	Crigler-najjar syndrome, type ii	Enrichment	UGT1A1, UGT1A7, UGT1A9	7.20
5	Gilbert syndrome	Enrichment	UGT1A1, UGT1A7, UGT1A9	7.06
6	Bilirubin metabolic disorder	Enrichment	UGT1A1, UGT1A7, UGT1A9	7.06
7	Colchicine resistance	Enrichment	ABCB1	3.23
8	Uric acid concentration, serum, quantitative trait locus 1	Enrichment	ABCG2	3.23
9	Encephalopathy, acute transient	Enrichment	ABCB1	3.23
10	Inflammatory bowel disease 13	Enrichment	ABCB1	3.23
11	Blood group, junior system	Enrichment	ABCG2	3.23
12	Vitamin d-dependent rickets, type 3	Enrichment	CYP3A4	3.23
13	Drug metabolism, poor, cyp2d6-related	Enrichment	CYP2D6	3.05
14	Severe primary trimethylaminuria	Enrichment	FMO3	3.05
15	Neonatal nephrocutaneous inflammatory syndrome	Enrichment	EGFR	2.75
16	Neonatal inflammatory skin and bowel disease	Enrichment	EGFR	2.75
17	Glaucoma 1, open angle, a	Enrichment	CYP1B1	2.75
18	Anterior segment dysgenesis 6	Enrichment	CYP1B1	2.75
19	Trimethylaminuria	Enrichment	FMO3	2.75
20	Primary trimethylaminuria	Enrichment	FMO3	2.75
21	Primary congenital glaucoma	Enrichment	CYP1B1	2.75
22	Coumarin resistance	Enrichment	CYP2C9	2.58
23	Cowden syndrome 1	Enrichment	EGFR	2.45
24	Lung squamous cell carcinoma	Enrichment	EGFR	2.45
25	Glaucoma 3, primary infantile, b	Enrichment	CYP1B1	2.45
26	Squamous cell carcinoma, head and neck	Enrichment	EGFR	2.38
27	Juvenile glaucoma	Enrichment	CYP1B1	2.35
28	Glaucoma, primary open angle	Enrichment	CYP1B1	2.28
29	Anterior segment dysgenesis 5	Enrichment	CYP1B1	2.28
30	Glaucoma 3, primary congenital, a	Enrichment	CYP1B1	2.21
31	Epilepsy, idiopathic generalized	Enrichment	ABCB1	2.19
32	Lung non-small cell carcinoma	Enrichment	EGFR	2.19
33	Lip and oral cavity carcinoma	Enrichment	EGFR	2.15
34	Lung cancer susceptibility 3	Enrichment	EGFR	2.08
35	Peters-plus syndrome	Enrichment	CYP1B1	2.05
36	Gliosarcoma	Enrichment	EGFR	2.03
37	Hypertension, essential	Enrichment	CYP3A5	2.00
38	Giant cell glioblastoma	Enrichment	EGFR	2.00
39	Arteriovenous malformations of the brain	Enrichment	EGFR	1.95
40	Anterior segment dysgenesis	Enrichment	CYP1B1	1.88
41	Bladder cancer	Enrichment	EGFR	1.77
42	Lung cancer	Enrichment	EGFR	1.73
43	Ovarian cancer	Enrichment	EGFR	1.24
44	Inherited cancer-predisposing syndrome	Enrichment	EGFR	1.12

¹ WikiPathways

² PubChem

³ R&D Systems

⁴ Reactome

⁵ GeneGo (Thomson Reuters)

⁶ QIAGEN

⁷ PharmGKB

⁸ Cell Signaling Technology

⁹ Sino Biological

¹⁰ Tocris

¹¹ MalaCards

Erlotinib Pathway, Pharmacokinetics

Pathway Network for Erlotinib Pathway, Pharmacokinetics

Pathway network for the Erlotinib Pathway, Pharmacokinetics SuperPath

Member Pathways for Erlotinib Pathway, Pharmacokinetics

Pathways in the Erlotinib Pathway, Pharmacokinetics SuperPath

Gene overlap in member pathways for Erlotinib Pathway, Pharmacokinetics SuperPath

Associated Genes for Erlotinib Pathway, Pharmacokinetics

Associated Disorders for Erlotinib Pathway, Pharmacokinetics

Disorders associated with Erlotinib Pathway, Pharmacokinetics SuperPath

STRING Interaction Network for Erlotinib Pathway, Pharmacokinetics

Sources for Erlotinib Pathway, Pharmacokinetics